(Q54687755)

2 June 2018

meta-analysis

0 references

title

Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials. (English)

1 reference

2 June 2018

0 references

1 reference

1

1 reference

2 June 2018

author name string

Aleksandra Mieczkowska

series ordinal

2

1 reference

2 June 2018

Daniel Chappard

series ordinal

3

1 reference

2 June 2018

publication date

22 November 2013

1 reference

2 June 2018

published in

Journal of diabetes

1 reference

2 June 2018

volume

6

1 reference

2 June 2018

issue

3

1 reference

2 June 2018

page(s)

260-266

1 reference

2 June 2018

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Optimal bone mechanical and material properties require a functional glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

The murine glucagon-like peptide-1 receptor is essential for control of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Bone loss accompanying voluntary weight loss in obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Weight loss from maximum body weight among middle-aged and older white women and the risk of hip fracture: the NHANES I epidemiologic follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Receptors and effects of gut hormones in three osteoblastic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12102

21 January 2018

Identifiers

DOI

10.1111/1753-0407.12102

1 reference

2 June 2018

PubMed ID

24164867

1 reference

2 June 2018